Clinical Trials Sponsored by Recepta Biopharma

Total 1972 results

Recepta Biopharma

Terminated

Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Brazil
Recepta Biopharma

Completed

In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides

Metastatic Cancer

Brazil
Recepta Biopharma

Completed

Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cancer

Brazil
Instituto do Cancer do Estado de São Paulo
Recepta Biopharma; Fundação Faculdade de Medicina

Terminated

HumanaH - Hu3s193 in the Treatment of Advanced Breast Cancer After Hormonal Therapy

Breast Cancer

Brazil
Lantu Biopharma

Not yet recruiting

An Open-label Study of a Gene Therapy Product in Beta-Thalassemia

Beta-Thalassemia
POINT Biopharma

Not yet recruiting

[(A)c-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, ToLerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL)

Prostate Cancer | Biochemically Recurrent Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer
Huons Biopharma

Not yet recruiting

To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Glabellar Lines
Vor Biopharma

Recruiting

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Leukemia, Myeloid, Acute

United States
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Estonia, Canada, France, Chile
United BioPharma

Not yet recruiting

Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

Chronic Idiopathic Urticaria
Kinnate Biopharma

Active, not recruiting

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

Intrahepatic Cholangiocarcinoma | Urothelial Carcinoma | Solid Tumor, Adult

United States, Korea, Republic of, Taiwan, China, Denmark, Spain
NImmune Biopharma

Terminated

Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease

Crohn's Disease

United States
CTI BioPharma

Completed

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States
NImmune Biopharma

Completed

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

Australia
NImmune Biopharma

Withdrawn

Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease

Crohn's Disease
Theravance Biopharma

Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (OAK)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Portugal, United Kingdom, France, Denmark, Ukraine, Israel, Estonia, Poland, Italy, Russian Federation, Australia, Austria, Bulgaria, Canada, Germany, New Zealand
Theravance Biopharma

Terminated

Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA)

Ulcerative Colitis (UC)

United States, Australia, Bulgaria, Canada, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Romania, Serbia, Slovakia, South Africa, Spain, Taiwan, Ukraine
DS Biopharma

Completed

Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients

Atopic Dermatitis

United States, South Africa
Theravance Biopharma

Completed

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (SEQUOIA)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Israel, Hungary, Portugal, Australia, Canada, Germany, Russian Federation, Estonia, France, Italy, United Kingdom, Denmark, Poland, New Zealand, Austria, Bulgaria, Ukraine
United BioPharma

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Urticaria Chronic

Taiwan
Theravance Biopharma

Completed

Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response

Asthma

United Kingdom
Theravance Biopharma

Completed

Phase 2 Study of TD-9855 to Treat Fibromyalgia

Fibromyalgia

United States
CTI BioPharma

Completed

Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant (PIX-R)

Diffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 Lymphoma

United States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
Theravance Biopharma

Completed

Single Ascending Dose Study of TD-0714 in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-1473 for Active Ulcerative Colitis (UC)

Ulcerative Colitis, Active Severe | Ulcerative Colitis, Active Moderate

United States, Georgia, Moldova, Republic of, Romania
Theravance Biopharma

Completed

Single and Multiple Ascending Dose Study of TD-8236 by Inhalation

Asthma

United Kingdom
Theravance Biopharma

Completed

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

Opioid-induced Constipation (OIC)

United States
Theravance Biopharma

Completed

A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation

Opioid Induced Constipation

United States
Theravance Biopharma

Completed

A Multiple Dose Study of TD-1211 in Healthy Volunteers and Patients With Opioid-Induced Constipation

Healthy | Opioid-induced Constipation

United States
Theravance Biopharma

Completed

TD-1211 IV/Oral Mass Balance Study

OIC

United States
Theravance Biopharma

Completed

TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Staphylococcal Skin Infection

United States
Theravance Biopharma

Completed

TD-1607 MAD Study in Healthy Subjects

Infections | Bacterial Infections

United States
Theravance Biopharma

Completed

Single and Multiple Ascending Dose, First-in- Human Study in Healthy Subjects

Healthy

United States
Theravance Biopharma

Completed

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

United States
CTI BioPharma

Terminated

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy. (PIONEER)

NSCLC

United States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
CTI BioPharma

Terminated

Arsenic Trioxide in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

Canada, United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
NuSirt Biopharma

Completed

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

Obesity

United States
DS Biopharma

Completed

Efficacy and Steroid Sparing Potential Study of DGLA Cream in Early Childhood Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Ireland
Array BioPharma

Completed

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Metastatic Colorectal Cancer

United States, Australia, Belgium, Canada, France, Israel, Italy, Netherlands, Singapore, Spain
DS Biopharma

Completed

Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects

Healthy

Ireland
Pronova BioPharma

Completed

Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects

Healthy

United Kingdom
Pronova BioPharma

Completed

Bioavailability of Omega-3 Food Supplements in Healthy Subjects

Healthy

United Kingdom
Pronova BioPharma

Completed

[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study

Healthy

United Kingdom
CTI BioPharma

Completed

A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (RAPID)

Diffuse Large-Cell Lymphoma

United States, Germany, Canada, Italy, France
CTI BioPharma

Completed

Phase I/II CT 2106 and 5-FU/FA in Colorectal Cancer

Colorectal Cancer

Italy
SmartNuclide Biopharma

Recruiting

Phase I Clinical Trial of 68Ga-NOTA-SNA002

Solid Tumor | Positron-Emission Tomography(PET)

China
Comanche Biopharma

Recruiting

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

Healthy Volunteer Study

United States
SPARK Biopharma

Recruiting

SB17170 Phase 1 Clinical Trial in Solid Tumors

Solid Tumor

Korea, Republic of

Clinical Trials Sponsored by Recepta Biopharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations